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Abstract 
Acute ischaemic stroke is a leading cause of death in Canada and should be a priority in 
health care. This paper defines acute ischaemic stroke and provides current statistics, 
economic costs, risk factors, treatments, and management options. A gap between current 
practice and literature is identified. Specific treatments of anticoagulant and antiplatelet 
therapy are explored through systematic reviews, clinical trials, and national guidelines. 
Considerable consistency in research findings have led to evidenced-based guidelines. 
Implications for practice, including barriers and facilitators to incorporating evidence-based 
recommendations are identified. The study concludes with an identification of the need for 
clinical practice guidelines in Northern Health along with the implementation of current 
provincial guidelines that will provide best patient care in treating patients with acute 
ischaemic stroke. 
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Anticoagulant Versus Antiplatelet Therapy for Acute Ischaemic Stroke 
Acute ischaemic stroke (AIS) is a leading cause of death in Canada and should be a 
priority in health care. This paper defines AIS and provides current statistics, economic costs, 
risk factors, treatment and management options. A gap between current practice and 
literature is identified, and the efficacy of anticoagulant and anti platelet therapy are 
determined through systematic reviews, clinical trials, and national guidelines. 
Background 
Cerebrovascular disease is a frequently occurring neurologic disorder that is 
characterized by the sudden loss of circulation to an area of the brain (Becker, 2006). Two 
broad types of cerebrovascular disease resulting from brain abnormalities are hemorrhagic 
and ischaemic stroke (Harrison's Practice, 2007). Diseases ofthe circulatory system 
accounted for 74,824 deaths in 2001 , about 34% of the total deaths in Canada; 21 % of 
disease due to the circulatory system were attributed to stroke (Statistics Canada, 2004). 
Stroke is the third leading cause of death in Canada: seven percent of all deaths in Canada 
are due to stroke (Heart and Stroke Foundation, 2008). Between 40,000 and 50,000 
Canadians are hospitalized for strokes every year (Health Canada, 2006) and about 15,000 of 
those strokes are fatal (Health Canada, 2006). According to the British Columbia Vital 
Statistics Agency, six British Columbians die each day from cerebrovascular disease (2006). 
British Columbia Vital Statistics Agency (2006) reports a downward trend of 
cerebrovascular mortality with 409 deaths from 2001 to 2006 in the Northern Health 
Authority. 
According to the Heart and Stroke Foundation (2008), of the Canadians who have a 
stroke, 15% will die soon after the stroke, 10% will recover completely, 25% will recover 
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with minor disability, 40% are left with moderate to severe impairment, and 10% are 
severely disabled and require long-term care. Disabilities may range from slight weakness of 
a hand to permanent hemiparesis. A stroke survivor has a 20% chance of restroke within two 
years (Health Canada, 2006). This paper will deal specifically with AIS as it is the most 
common type of stroke. 
Financial Cost of Stroke 
Stroke costs the Canadian economy 2.7 billion dollars per year in physician services, 
hospital costs, lost wages, and lost productivity, with an average of$27,500 per stroke (Heart 
and Stroke Foundation, 2008). Stroke cost in British Columbia is estimated to be greater than 
$327 million annually (HSFBC&Y, 2005). Lindsay et al. (2008) contend that organized 
stroke care over a 20-year period could prevent 160,000 strokes; a projected $8 billion in 
savings to the Canadian health care system. 
Risk Factors for Stroke 
After age 55, the risk of stroke doubles every 10 years and more women than men die 
from stroke at all ages (Health Canada, 2006; Heart and Stroke Foundation, 2007). Some 
pre-existing medical conditions as well as some lifestyle factors can put people at a higher 
risk for stroke. Risk factors for stroke include hypertension, diabetes, hyperlipidemia, atrial 
fibrillation, atherosclerosis, recent myocardial infarction, family, and/or personal history of 
heart disease (Harrison's Practice, 2007; Health Canada, 2006). Other risk factors include 
cigarette smoking, acquired immune deficiency syndrome (AIDS), recreational drug use, and 
heavy alcohol consumption (Center for Disease Control and Prevention, 2007). 
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Causes of Stroke 
While hemorrhagic or 'bleeding' stroke accounts for 15-20 % of total strokes, acute 
ischaemic stroke (AIS) accounts for 80-85% of all strokes. AIS is caused by emboli, 
thrombus, or systemic hypoperfusion that blocks an artery leading to the brain (Granitto, 
2008). Embolic causes due to atrial fibrillation, patent foramen ovale, and low ejection 
fraction account for 45% of ischaemic strokes. Thrombus due to plaque buildup and 
narrowed arteries accounts for 30% of ischaemic strokes. The remaining 25% of ischaemic 
strokes are attributable to systemic hypoperfusion, hypercoagulable states, and cryptogenic 
causes (Granitto ). With the major proportion of strokes being ischaemic, it is prudent for this 
project to determine the best evidence for treating AIS. 
Clinical Presentation of Stroke 
The usual clinical presentation of AIS include neurologic impairment such as 
transient blindness, diplopia, dizziness, headache, sensory deficiencies, speech problems, 
motor difficulties, and weakness or numbness (Heart and Stroke Foundation of Canada, 
2007). Severe impairment may include a loss of consciousness after the event, coma, or 
death (Tierney, 2007). Generally, the greater or larger the cerebral vessel involved, the 
greater the risk of morbidity and mortality. 
Diagnosing Stroke 
Emergency non-contrast head computed tomography (CT) is mandatory for 
distinguishing ischaemic from hemorrhagic stroke. A head CT scan is a crucial diagnostic 
tool in the evaluation of this cause of stroke, since patients with AIS may be eligible to 
receive thrombolytics therapy, while patients with hemorrhagic stroke are best treated with a 
completely different therapeutic pathway (Becker, 2006). This paper will focus on the 
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treatment of AIS with specific interest in anticoagulant and antiplatelet therapy. Treatment of 
AIS with thrombolytics will be briefly discussed due to the importance of the medication in 
treating AIS. 
Treatment of AIS 
The guiding principle in AIS treatment is the phrase Time is Brain. This refers to the 
need to act quickly because brain tissue is lost with every minute that passes. Treatment of 
AIS includes three different medications: thrombolytics, anticoagulants, and antiplatelets. 
This paper will define the three classes of medications, however, the focus will be on 
antiplatelet therapy versus anticoagulant therapy because there appears to be a considerable 
discrepancy between individual practice and recommended guidelines with regard to the two 
treatments. 
Thrombolytics 
Granitto (2008) asserts that to date, the use of intravenous tissue plasminogen 
activator tPA is the sole thrombolytic agent approved for use in patients with AIS. This drug 
class is commonly referred to as 'clot buster' medication and has been used since 1996. 
Dissolving the clot will reduce damage to the brain, therein reducing the effects of the stroke 
and decreasing permanent disability (AHA, 2008). Tierney (2007) states that tPA decreases 
the risk of disability by 30% in patients who receive the drug within 3 hours of onset of AIS. 
Effective and rapid treatment of AIS increases quality of life and decreases the mortality rate. 
The use of tP A carries the risks of intracerebral hemorrhage and angioedema with possible 
airway compromise, all which are serious and life threatening side effects (Adams et al., 
2007). TP A should therefore only be used within the confines of stroke guidelines, and 
initiated only after AIS is confirmed by a head CT scan. Since ischaemic stroke must be 
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accurately diagnosed by CT scan, many patients are unable to receive the clot busting 
therapy due to time constraints. The 3 hour time frame for use oftPA limits its use in rural 
and remote areas of British Columbia. In addition to time, there are many inclusion criteria 
that must be met for a patient with AIS to receive tP A such as medical history and current 
illnesses. TP A has substantial costs including the medication itself and the specially trained 
medical/nursing staff required to administer it. 
Anticoagulants 
Anticoagulant drug therapies include heparin, low molecular weight heparin 
(LMWH), and warfarin. Warfarin reduces the synthesis of clotting factors by depleting the 
body's store of vitamin K and takes 48 to 72 hours to become therapeutic (Valentine & Hull, 
2008). Warfarin causes twice as many hemorrhages as aspirin, particularly in patients with a 
history ofbleeding or genetic disorder and in elderly patients (Hankey, 2005). Warfarin has a 
narrow therapeutic window, requires frequent dosing changes, continuous monitoring, and is 
affected by numerous drug and food interactions (Hankey). Heparin and LMWH prevent 
blood clotting by potentiating the action of antithrombin therein inactivating thrombin and 
preventing the conversion of fibrinogen to fibrin (Valentine & Hull, 2007). While the 
heparins also have a narrow therapeutic window, and require twice daily injections, the 
duration of action is about 12 hours compared to 3-5 days for warfarin. However, like 
warfarin, the heparins also have similar bleeding complications, which could offset any 
benefits. Hemorrhagic stoke will develop if an AIS is treated with warfarin or heparin 50% 
more frequently than if treated with aspirin (Berge & Sandercock, 2002). 
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Antiplatelets 
Anti platelet drug therapies include aspirin and thienopyridine derivatives ( clopidogrel 
and ticlopidine). Aspirin, clopidogrel, and ticlopidine block prostaglandin synthetase action 
which prevents formation of the platelet aggregating substance thromboxane (Lexi-Comp, 
2008a; Lexi-Comp, 2008b ). Aspirin has been used for centuries for medicinal purposes and 
is also quite inexpensive compared to newer antiplatelet drugs. Aspirin is easy to administer 
and continuous monitoring is not required for patients who receive this medication. Aspirin 
is not without potential side effects, which include allergic reactions, upper gastrointestinal 
upset, gastrointestinal bleeding, and rash (Hankey, 2005). However, the side effects of the 
theinopyridine derivatives are greater in severity compared to those occurring with aspirin 
and include hemorrhage, diarrhea, rash, and neutropenia (Hankey). Current Canadian and 
American clinical practice guidelines state that anticoagulant therapy is not recommended for 
AIS and that antiplatelet therapy using aspirin should be initiated immediately after 
confirmation of AIS by computed tomography (CT) scan (Adams, et al, 2007; Canadian 
Stroke Strategy, 2006). 
Management of AIS 
Physicians have used anticoagulants to treat patients with AIS for over 50 years, yet 
despite its longstanding and widespread use, anticoagulant therapy is the subject of much 
debate (Adams et al, 2007). Adams et al. assert that disagreements exist regarding the 
usefulness of emergency anticoagulation, the best agent to administer, the preferred route of 
administration, use of a bolus dose to initiate treatment, the level of anticoagulation required, 
and the duration of treatment. Physicians often erroneously prescribe anticoagulants to 
patients with recent stroke in an effort to prevent early recurrent stroke and to improve 
7 
neurological outcomes (Adams et al.). Nurse Practitioner Stroke Guidelines assert that early 
anticoagulant therapy does not decrease the risk of neurological worsening (Granitto, 2008). 
In the past decade, guidelines for stroke management have included 
recommendations on medication use in AIS. These recommendations have changed over the 
years to incorporate new research findings. Because health care providers continue to 
prescribe both anticoagulant and antiplatelet therapy for AIS, the current evidence on these 
therapies merits review. 
Study Question 
The study question explored in this project is: In patients with acute ishaemic stroke, 
does antiplatelet therapy as compared to anticoagulant therapy reduce the incidence of 
restroke and mortality? The patient population consists of people diagnosed with AIS. The 
intervention of interest is the use of anti platelet therapy compared with anticoagulant 
therapy. The outcome of interest is which group of patients has had a more positive outcome, 
specifically, reduced incidence of restroke and decreased mortality. 
Literature Review 
Sources and Research Processes 
Databases used to find evidence to address the question include: Cochrane Database 
of Systematic Reviews (CDSR), National Guidelines Clearinghouse (NGC), Cumulated 
Index ofNursing and Allied Health Literature (CINAHL), MEDLINE, Science Direct, 
Pubmed, Ovid, Blackwell Synergy, Evidence-based Medicine (EBM) reviews, and 
UpToDate. The key words used included: acute ishaemic stroke, antiplatelet, anticoagulant, 
aspirin and stroke, stroke nursing care, antiplatelet$ and anticoagulant$, stroke prevention, 
ishaemic stroke and study$, acute ishaemic stroke and trials, cerebrovascular accident, 
8 
vascular infarct, evidence and prevention, and stroke and guidelines. Inclusion criteria were 
patients diagnosed with AIS and treated with either anticoagulant, antiplatelet therapy, or 
combination therapy. The patients in the studies included men and women of varying 
ethnicities and ages. The systematic reviews were chosen because the reviewers 
independently selected studies for inclusion, assessed the quality of trials, and extracted the 
data. The search resulted in three single studies and trials (a RCT, a multi-centre trial, and a 
case cross-over study) totaling 4,900 patients, four systematic reviews totaling 104,160 
patients, and six national guidelines for review and analysis. 
Single Studies and Trials 
Randomised controlled trials and observational studies provide complimentary 
evidence to the more powerful systematic review (Barton, 2000) . The following single 
studies and trials compare anti platelet agents for the treatment of diagnosed AIS. The 
antiplatelet agents included in these studies and trials are aspirin, ticlopidine, clopidogrel, 
and a combination of aspirin and clopidogrel. 
Grau et al. ' s, (2003) case-cross over study of 31 patients compared clopidogrel 75mg 
and aspirin 300 mg each as monotherapy and as combination therapy. Patients diagnosed 
with AIS and treated with aspirin for secondary prevention, received clopidogrel alone, or a 
combination of clopidogrel and aspirin for four weeks. Grau, et al. found that while 
combined therapy indicates a lower risk of thrombosis, it increases the risk of hemorrhage. 
However, in a multi-centre trial involving 1809 African-American patients diagnosed with 
stroke, within 90 days of onset, in over 60 cities, aspirin 650 mg was found to be as effective 
as ticlopidine 500 mg in preventing restroke (Gorlick, 2003). The potential for serious side 
effects was found in the patients receiving ticlopidine, therefore outweighing the benefits of 
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administering the medication. Hass et al. ' s ( 1989) RCT involving 3069 patients diagnosed 
with recent transient or mild persistent focal cerebral or retinal ischaemia compared 
ticlopidine 500 mg to aspirin 1300 mg. Hass et al. found ticlopidine to be only 2 percent 
more effective than aspirin for preventing restroke or death in the following three years. 
However, the study also found that the side effects ofticlopidine were doubled in 
comparison to those of aspirin. Noted in this study are the large dose of aspirin and the age of 
the study. While the above three studies are not as credible on their own as are systematic 
reviews and national guidelines, the findings are similar to the fmdings of the more credible 
evidence and are useful in the context of this paper. They were chosen for this project 
because they address the pressing study question, were in peer reviewed journals, and are 
examples of well done studies. Evidence from the above studies and trials clearly determines 
that aspirin should be administered instead of other antiplatelet medications, however, the 
question of appropriate aspirin dosage remains. While these single studies and trials are 
included in systematic reviews and national guidelines, they are also valuable as evidence to 
support individual health care providers as they search for evidence-based provision of care 
to patients with AIS. 
Systematic Reviews 
Systematic reviews of randomized controlled trials are "traditionally the gold 
standard for judging the benefits of treatments, mainly because it is conceptually easier to 
attribute any observed effect to the treatment being compared" (Barton, 2000). In the 
following four systematic reviews, one examines the use of anti platelet therapies clopidogrel 
and ticlopidine compared to aspirin for the prevention of AIS. The second examines the 
anticoagulant therapy of unfractionated and low molecular weight heparin compared to 
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aspirin. The third examines the anticoagulants heparinoids and warfarin compared to aspirin. 
The fourth compares patients given aspirin versus no aspirin therapy. 
Hankley, Sudlow, and Dunbabin's (2000) systematic review of four double blind 
randomized trials included 22,656 patients diagnosed as high risk. The study compared 
clopidogrel and ticlopidine versus aspirin for preventing AIS in high risk patients. High-risk 
patients were defined as those identified as having TIAs or previous clinical manifestations 
of disease in cerebral, coronary, or peripheral circulation systems. The average age was 63 
and two thirds of the patients were men. The study sample may not be completely 
generalizeable in that stroke occurs more frequently in women. Comparisons were made 
between clopidogrel 75 mg, ticlopidine 250 mg, and aspirin 325 mg. The theinopyridines 
were found to be slightly more effective than aspirin in preventing stroke in high risk 
patients, however, the side effects of skin rash and diarrhea increased with clopidogrel (30%) 
and ticlopidine (>60%). Neutropenia was seen in patients who were administered ticlopidine. 
Given the cost comparison and the side effects of the theinopyridines compared to aspirin, 
aspirin administration is clearly the first choice in treating patients with AIS. 
Berge & Sandercock's (2002) systematic review of 16, 558 patients in four RCTs 
compared unfractionated heparin (UFH) with low molecular weight heparin (LMWH). 
Aspirin was used as a control in all trials however, and no specific dose of aspirin was 
identified. The patients had been diagnosed with AIS by CT Scan or MRI within 48 hours of 
onset of symptoms. Berge & Sandercock found that treatment with the anticoagulant heparin 
was of no more value than treatment with aspirin. They noted that heparin use caused 
increased bleeding complications equivalent to 20 more deaths per 1000 patients and restroke 
equivalent to 10 more restrokes per 1000 patients. Berge & Sandercock contend that aspirin 
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is inexpensive, easy to use, and is the "standard" treatment for patients with AIS. This 
systematic review should be recognized as one of the higher levels of evidence in the 
recommendation of using aspirin instead of anticoagulant therapy based on the large number 
of participants and the generalizability of the findings. 
Gubitz, Sandercock & Counsell ' s (2007) systematic review of23,547 patients in 22 
RCTs compared the anticoagulants, unfractionated heparin, low molecular weight heparin, 
and warfarin versus aspirin control groups. They found that the immediate use of low-
molecular-weight heparin, heparinoids, oral anticoagulants, and thrombin inhibitors 
increased the risk of major extracranial and intracranial hemorrhages equivalent to nine 
people per 1000 and prevented the equivalent of nine recurrent ischaemic strokes per 1000 
patients compared to the aspirin control group. They concluded that the use of anticoagulant 
therapy is not associated with short or long term benefit and is associated with an increased 
risk of major intracranial and extracranial hemorrhages. Gubitz et al. found no evidence that 
anticoagulant therapy reduced the odds of death from all causes at the end of follow-up (odds 
ratio =1.05 , 95%; confidence interval 0.98 to 1.12). This systematic review should be 
recognised as having major implications for clinical practice and stronger than the previous 
2000 and 2002 systematic reviews in that it is 5-7 years newer. 
Sandercock, Gubitz, Foley, & Counsell's (2007) systematic review of nine RCTs of 
41,399 patients assessed the efficacy and safety of aspirin in patients diagnosed with AIS. 
They found that aspirin (160 mg - 300 mg) given within 48 hours of stroke onset reduced the 
risk of restroke equivalent to 7 per 1000 patients at a six month follow up compared to 
patients not given aspirin. They concluded that aspirin reduces the risk of restroke without 
major risk of hemorrhagic complications and improves long term outcome. Sandercock et al. 
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found that mortality was reduced equivalent to 13 patients per 1000 for patients allocated to 
aspirin. This systematic review is different from the previous ones in that aspirin and aspirin 
dosage is the only agent studied, most likely due to the fact that aspirin has been the 
presumed treatment for AIS. Of major importance in this systematic review is the dosage of 
aspirin recommended, which is a range of 160- 300 mg. 
Clinical Practice Guidelines 
Fletcher (2007) states that clinical practice guidelines (CPGs) are the new reality in 
medicine and that CPGs are "recommendations for clinicians about the care of patients with 
specific conditions .. . based on the best available research evidence and practice experience". 
CPGs contain two parts, beginning with the foundation of a systematic review of the current 
research evidence-based on a specific clinical question which is focused on the strength of 
evidence on which clinical decision making for the particular condition is based. The second 
part, "which involves both the evidence and the value judgments, is a set of 
recommendations for how patients with that condition should be managed, everything else 
being equal" (Fletcher). The purpose of a CPG is to guide and help the health care provider 
take better care of patients. CPGs are suggestions for care, rather than rules, and there will 
always be patients who require independent management. However, it is crucial to critique 
and recognise credible guidelines because thousands of guidelines, which vary in quality 
have been published. Fletcher states that the hallmarks for credible guidelines can be 
recognized by several easily identifiable characteristics which include: expertise, evidence-
based, broad-based, regency, imprimatur, implementation, and renew (Appendix A). Fletcher 
also defines the criteria for reporting clinical practice guidelines (Appendix B). 
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National Guideline Clearinghouse 
The National Guideline Clearinghouse (NGC) web site is maintained by the United 
States Federal Agency for Healthcare Quality in conjunction with the American Medical 
Association and the American Association of Health Plans. The NGC database houses 
guidelines from most major medical organizations but does not include every guideline 
(Fletcher, 2007). The NGC does not develop, produce, approve, or endorse the guidelines 
represented on the website. All guidelines on the website "are produced under the auspices of 
medical specialty societies, relevant professional associations, public or private 
organizations, other government agencies, healthcare organizations or plans, and similar 
entities" (NGC, 2007). 
The following four guidelines from NGC state specifically the appropriate use and 
dose of aspirin, and discuss other antiplatelet and anticoagulant therapies. Anderson et al. 
(2007) sponsored by the Institute for Clinical Systems Improvement (ICSI) and funded by 
seven insurance companies found that there is no evidence to support the use of 
anticoagulant therapy for the treatment of AIS. They recommend that aspirin (160 mg- 325 
mg) should be given orally, rectally or by nasogastric (NG) tube when treating patients with 
confirmed AIS. Anderson, et al. recommends that patients who receive thrombolytics should 
also receive aspirin 24 hours post thrombolytics to prevent restroke. Clopidogrel 75 mg 
orally may be used in those who are allergic to aspirin. Anderson et al. do not support the use 
of anticoagulants (heparins) for treatment of acute ishaemic stroke. While this guideline is 
similar in its recommendations to the above systematic reviews, the fact that this guideline 
was sponsored by 7 insurance companies make it less likely that health care providers will 
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incorporate it into their practice. As Fletcher (2007) states "clinicians as less likely to believe 
in guidelines prepared by managed care organizations and insurance companies". 
An earlier NCG guideline by Albers, Amarenco, Easton, Sacco, and Teal (2004), 
which was sponsored by the American College of Chest Physicians - Medical Specialty 
Society and funded by five insurance companies, recommends aspirin (160 mg- 325 mg) in 
favour of anticoagulant therapy in patients diagnosed with AIS and aspirin (50- 325mg) in 
patients with transient ischaemic attack (TIA). The authors also recommend aspirin-
clopidogrel combination, or clopidogrel 75 mg for patients who are intolerant of aspirin. 
However, Coull et al. (2002), whose study was funded by the American Academy of 
Neurology (AAN), recommend aspirin (160 mg -325 mg). They do not recommend any other 
antiplatelet therapy or anticoagulant therapy for AIS. Coull, et al. recommend that patients 
who have not been given thrombolytics and present within 48 hours of stroke should be 
administered aspirin. Goldstein, et al.'s (2006) guideline which is supported by the 
Cardiovascular Nursing Council and the Agency for Healthcare Research and Quality states 
that aspirin is useful to prevent first stroke in women. Goldstein, et al. does not recommend 
aspirin as prevention for the first stroke in men however, "[t]he use of aspirin is 
recommended for cardiovascular (including but not specific to stroke) prophylaxis among 
persons whose risk is sufficiently high for the benefits to outweigh the risks associated with 
treatment". Goldstein, et al. recommend aspirin as prevention for the first stroke in women, 
but does not state the dosage or the reasons supporting the recommendation. According to 
Fletcher (2007), clinicians are most likely to accept recommendations from their own 
specialty area and less likely to trust those from a government agency, therefore the 
recommendation from the AAN is a major reason why physicians and Family Nurse 
Practitioners could support aspirin use over other antiplatelet therapy. 
National Recommendations 
15 
The American Stroke Association (ASA) is a division of the American Heart 
Association and is dedicated to improving stroke prevention, treatment, and rehabilitation 
therapy, research, education, advocacy, and the development of scientifically based standards 
and guidelines (Acker, et al. 2007). The ASA developed a multidisciplinary Task Force that 
determined that there is a fragmented approach to care which currently exists and thereby 
poses significant obstacles to reducing the morbidity and mortality of stroke. 
The American Heart and Stroke Association (2007) state that "anticoagulation with 
the goal of preventing recurrent stroke, halting neurological worsening, or improving 
outcomes" after AIS is not recommended. Adams et al. (2007) prepared the American Stroke 
Association guidelines. Adams, et al. recommends administration of aspirin (325 mg) within 
24-48 hours after AIS is diagnosed. Adams et al. , do not recommend clopidogrel or 
clopidogrel combined with aspirin for AIS. 
The Canadian Stroke Strategy (CSS) (2006) states that all ischaemic stroke patients 
should be administered at least 160 mg of aspirin as a loading dose and then 50-325mg daily. 
For patients treated with tP A, aspirin should be delayed until 24 hours post thrombolysis. 
The Canadian Stroke Strategy does not support the use of other antiplatelet therapies unless 
aspirin is contraindicated (such as allergy) . Acute aspirin therapy reduces the risk of early 
restroke and long term therapy reduces the risk of ischaemic stroke, myocardial infarction, 
and vascular death. The Canadian Stroke Strategy recommends against the use of 
anticoagulant therapy for AIS. The American and Canadian national guidelines use multiple 
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sources of information including the Cochrane Database of systematic reviews, clinical 
evidence, clinical practice guidelines, meta-analysis, case reports, and journal reviews to 
make best recommendations. 
Discussion 
Evidence in the literature review clearly demonstrates that there is no benefit in using 
anticoagulant therapy over antiplatelet therapy in AIS prevention or treatment. In fact, 
anticoagulant therapy for patients with AIS is not recommended because anticoagulants 
cause more harm than benefit. Aspirin 160 - 325 mg/day for patients with acute ischaemic 
stroke is the evidence-based recommendation emerging from the literature. Basically, the 
only clinical questions remaining are regarding the best loading does of aspirin ( 160mg or 
325mg) to treat AIS, and the daily dose of aspirin (50mg or 325mg) to prevent restroke. 
Implications for Practice 
Best practices are not consistently applied to all people diagnosed with AIS resulting 
in a significant gap between what should be done and what is actually being done to provide 
quality care to Canadians (CSS). The major implication for practice within the primary 
health care setting is that the use of aspirin should be the preferred for treatment and 
prevention of acute ishaemic stroke and restroke. Daily aspirin can be used in primary, 
secondary, and tertiary health prevention of acute ischaemic stroke. Usual daily prophylactic 
dosage is 50- 325 mg depending on the patient's tolerance and the clinical situation (Gray, 
2003). Best practices that include these recommendations for AIS care have been developed 
and are in the process of being implemented in Canada and British Columbia. 
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Canadian and British Columbia Stroke Strategies 
The Canadian Stroke Strategy (CSS) is a joint initiative of the Canadian Stroke 
Network and the Heart and Stroke Foundation of Canada. The goal ofthe CSS is to help 
support an integrated approach to stroke prevention, treatment, and rehabilitation in every 
province and territory by 2010 (CSS, 2006). A national working group of the CSS developed 
the Best Practice Recommendations for Stroke Care: 2006 using a consensus-based process 
and extensive consultations in addition to a comprehensive literature review. Best practice 
guidelines prepared by national organizations that undergo careful review by representatives 
are of the most credible and influential as they are endorsed by respected national bodies and 
are subject to intense scrutiny by health care professionals (Fletcher, 2007). The CSS 
recommendations include everything from blood pressure management to brain imaging and 
treatment to patient rehabilitation (CSS, 2006). The CSS established the National Stroke 
Nursing Council in 2005 to promote leadership, communication, advocacy, education, and 
research into the area of stroke. The CSS states that there are frequent reports that new 
research in stroke does not always reach primary care providers and patients. 
The goal of the British Columbia Provincial Stroke Strategy (BCPSS) is to "reduce 
the social and economic burden of stroke in BC through optimal prevention and care, 
excellence in rehabilitation, and facilitation of successful community re-integration" 
(HSFBC&Y, 2005, p. 15). The BCPSS is based on four principles: comprehensive, 
coordinated, evidence-based, and province-wide care. The principles, when implemented, 
will improve the continuum of care, in that all health care providers throughout the province 
would follow the same standardized guidelines, which are based on evidence. The 
recommendation of the BCPSS is to adopt the national guidelines as outlined in the 
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Canadian Stroke Strategy Best Practice Recommendations: 2006. The Canadian Stroke 
Strategy (CSS) will provide "the impetus for all provinces and territories to achieve a 
coordinated and integrated approach to stroke prevention, treatment and rehabilitation by 
2010" (HSFBC&Y, 2005, p.8). 
Barriers and Facilitators 
In implementing or planning for change, barriers must be identified in order to choose 
the most appropriate intervention technique. Although the identification of barriers and 
facilitators to the implementation of clinical practice guidelines for stroke care goes beyond 
the purpose of this project, a few observations are made here. Lindsay et al. (2008) report 
that 77% of hospitals do not have a formal protocol for managing stroke and that the major 
factor accounting for varying stroke care is due to the lack of implementation of guidelines. 
Rita Sweeney RN, Clinical Lead in Acute MI and Stroke Project, who is identifying and 
implementing evidence-based practice recommendations for NHA based on the Provincial 
Stroke Strategy (Personal Communication, July, 2008) contends that there are similar 
barriers in Northern Health. 
Guideline implementation may also be hindered by individual barriers. A clinical 
practice guideline may be perceived as inconvenient or difficult to use. A guideline that 
recommends the elimination of an established clinical practice of administering 
anticoagulartts for stroke and implementing a new behaviour such as administering aspirin 
may be difficult for practitioners to accept (Buchan, 2006). The individual health care 
provider may not agree with a specific guideline or even the concepts of guidelines in 
general. Health care providers may also lack the motivation to change or may not feel 
competent to change. McKenna & Keeny (2004) found several specific barriers for 
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physicians to implement evidence-based guidelines: limited relevance of research to practice, 
difficulty keeping up with all of the current changes in primary care, and the ability to search 
for evidence-based information. The ability to search for evidence-based information is also 
noted by Gronseth (2004) as a barrier "results are mixed on whether educating physicians 
about evidence-based recommendations is sufficient to change physician behaviour" (p. 
335). Gronseth attributes the barriers as physician skepticism, patient expectations, fear of 
legal action, and distorted reimbursement systems. Similarly, Miles, Loughlin & Polychroius 
(2007) found that although physicians have a positive view of the evidence-based 
recommendations and easy access to them, the majority seldom use the internet to search for 
information due to time constraints. The Centre for Health Evidence (CHE) (2007) states that 
using the findings from systematic reviews constitutes evidence-based medicine and thereby 
"de-emphasizes intuition, unsystematic clinical experience, and pathophysiological rationale 
as sufficient grounds for clinical decision making, and stresses the examination of evidence 
from clinical research". However, CHE also appreciates the new skills required by physician 
which includes efficient literature searching as well as the application of formal rules in 
evaluating the clinical literature. It is likely that inconsistent care of patients with AIS is 
related to the lack of clinical practice guidelines for AIS , differing opinions and 
interpretations of evidence by physicians, and differing physicians' training and experience 
(Grimshaw et al., 2001). 
Although inconsistent practices in the treatment of AIS are experienced in Northern 
Health facilities, there are current actions underway that have the potential to remedy this 
concern. The work of the Acute MI and Stroke Project which includes assessment of 
facilities and staff, education, and guideline implementation, is an important initiative for the 
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health of the people who reside in the Northern Health Authority (Grimshaw et al. (2001). 
supports this approach, in stating that the 'effects of implementing guidelines across a range 
of settings generally observe improvement in the process of care" (p. 41 ). 
Implementing Evidence-based Practice 
Evidence-based practice (EBP) "is the conscientious use of current best evidence in 
making decisions about patient care" (Sackett, Straus, Richardson, Rosenberg, & Haynes, 
2000 in Melnyk & Fineout-Overholt, 2005, p.6). It is crucial that all health care providers 
working in primary care base their practice on the most current evidence. Family Nurse 
Practitioners have been introduced as primary health care providers in British Columbia, and 
are accountable for providing quality patient care. As Family Nurse Practitioners are 
prescribing medication, caring for people with chronic diseases, and most importantly, 
helping to prevent disease and injury and to promote health, they must be current in their 
knowledge because so much of the FNP's role is teaching patients and their families about 
their disease and their medication. FNPs, who are increasingly important members of 
primary healthcare teams have a responsibility to communicate guidelines effectively to 
colleagues through continuing education activities within the team. Through such venues as 
weekly rounds, newsletters, email, or journal clubs, FNPs may effect change to health care 
providers and health care recipients. 
Recommendations 
After a thorough review of the current available literature on the treatment of AIS, 
it is recommended that the CSS Canadian Best Practice Recommendations for Stroke Care 
be incorporated into the treatment of patients with AIS across Northern Health in particular 
with relation to the use of antiplatelet therapy and the avoidance of anticoagulant therapy. 
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The CSS recommendations are evidence-based and meet the criteria for credible guidelines 
as defined by Fletcher (2007). Further investigation in identifying and choosing appropriate 
interventions that will overcome the barriers to implementing new evidence-based clinical 
practice guidelines would merit investigation. 
Conclusion. 
Acute ishaemic stroke is a significant health concern for both health care practitioners 
and patients in Northern Health Authority. While there is an identified gap between current 
theory and practice of the administration of anti platelet versus anticoagulant therapy, 
substantial evidence-based research has demonstrated best treatment for patients with AIS. 
The research evidence recommends the administration of aspirin 160 mg- 325 mg over 
other antiplatelet agents, and recommends against anticoagulant therapy for the treatment of 
AIS. Implementing aspirin therapy in the prevention and treatment of AIS has considerable 
economic clinical and economic benefits in Northern Health. Additionally, it is essential for 
primary health care providers to develop or follow clinical practice guidelines based on 
research to support the best possible patient care. FNPs can play a significant role in this 
regard in the primary care team. FNPs emphasize health promotion and disease prevention in 
primary, secondary, and tertiary care. 
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Appendix A (reprinted from R. Fletcher, (2007). Clinical practice guidelines. UpToDate) 
Hallmarks of a credible guideline 
Expertise !Should include all relevant expertise bearing on the clinical decision 
Evidence-based Should have explict, scientifically credible, plans for finding all relevant 
research results, weighing the strength of the evidence, and providing 
rationale for decisions 
Broad-based 
Recency 
Imprimatur 
!
Should go beyond effectiveness to look at harm, cost, and other clinically-
relevant factors 
trhe guideline should not be out of date, relative to developments in its 
Wield 
!Guidelines by respected national organizations are more likely to be 
~redible 
Implementation ~uidelines should pay attention to how the recommendations can be 
ccomplished in practice, including the workforce and expertise necessary 
o do so 
Review ~uidelines should be shaped not just by the particular panel that drafted hem, but also by other members of the sponsoring society and other rganizations 
©2007 UpToDate® • customerservice@uptodate.com 
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Appendix B (Reprinted from R. Fletcher. (2007) Evidenced-based medicine. UpToDate 
c· r1ter1a f t" r . t" ·d r or repor mg c m1ca prac 1ce gu1 e mes 
Objective 
f. succinct statement of the objective of the guideline, including the targeted health problem, 
he targeted patients and providers, and the main reason for developing recommendations 
concerninq this problem for this population. 
Options 
Principle practice options that were considered in formulating the guidelines. 
Outcomes 
Significant health and economic outcomes identified as potential consequences of the 
practice options. 
Evidence 
Methods used to gather, select, and synthesize evidence, and the date of the most recent 
evidence obtained. 
Values 
Persons and methods used to assign values (relative importance) to potential outcomes of 
alternative practice options. 
Benefits, Harms and Costs 
The type and magnitude of the main benefits, harms, and costs that are expected to result 
from guideline implementation. 
Recommendations 
,A.brief and sp_ecific list of key recommendations. 
Validation 
r-he results of any external review, comparison with guidelines developed by other groups, 
or clinical testinq of quideline use. 
Sponsors 
Key persons or groups that developed, funded, or endorsed the guideline. 
Adapted from Haywood, SA, Wilson, MC, Tunis, SR, eta/, Ann Intern Med 1993; 
118:731. 
